BURLINGTON, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will participate in three upcoming investor conferences.
Jefferies London Healthcare Conference 2025
Tuesday, November 18, 2025
Waldorf Hilton, London
Dorian LeBlanc, CFO, will present at 8:00 AM GMT
Wolfe Research 7th Annual Healthcare Conference
Wednesday, November 19, 2025
Wolfe NYC Offices, New York, NY
David Roberts, President, will present at 10:40 AM ET
Piper Sandler 37th Annual Healthcare Conference
Thursday, December 4, 2025
Lotte Palace, New York, NY
Dorian LeBlanc, CFO, will present at 3:20 PM ET
About LeMaitre
LeMaitre is a provider of devices, implants, and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. For more information about the Company, please visit www.lemaitre.com.
LeMaitre is a registered trademark of LeMaitre Vascular, Inc.
Contact:
Sandra Millar
LeMaitre Vascular, Inc.
+1-781-425-1686
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$82.80 |
| Daily Change: | -0.15 -0.18 |
| Daily Volume: | 133,012 |
| Market Cap: | US$1.880B |
November 06, 2025 August 05, 2025 May 05, 2025 May 01, 2025 April 01, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
